Literature DB >> 22629552

Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.

Alexandra J Greenberg1, S Vincent Rajkumar, Dirk R Larson, Angela Dispenzieri, Terry M Therneau, Colin L Colby, Tara K Phelps, Shaji K Kumar, Jerry A Katzmann, Robert A Kyle, Susan L Slager, Celine M Vachon.   

Abstract

Previously, we reported increased risk of heavy-chain (HC) monoclonal gammopathy of undetermined significance (MGUS) among first-degree (1°) relatives of multiple myeloma (MM) or HC-MGUS probands. This study investigated whether there was comparable risk for light-chain (LC) MGUS among 911 relatives of the same HC-MGUS/MM probands versus a reference population of 21 463. Seventeen 1° relatives had LC-MGUS (adjusted prevalence = 1·7%, 95% CI = 0·9–2·6%). There was increased risk of LC-MGUS in relatives of MM probands (RR = 3·4, 95% CI = 2·0–5·5). We saw no increased risk in relatives of HC-MGUS probands. We conclude that the prevalence of LC-MGUS is significantly higher among 1° relatives of MM probands compared to the reference population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22629552      PMCID: PMC3375594          DOI: 10.1111/j.1365-2141.2012.09075.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Authors:  Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

2.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

3.  Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.

Authors:  Jerry A Katzmann; Roshini S Abraham; Angela Dispenzieri; John A Lust; Robert A Kyle
Journal:  Clin Chem       Date:  2005-03-17       Impact factor: 8.327

4.  Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

Authors:  M Drayson; L X Tang; R Drew; G P Mead; H Carr-Smith; A R Bradwell
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

5.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

6.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

7.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

8.  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.

Authors:  Celine M Vachon; Robert A Kyle; Terry M Therneau; Barbara J Foreman; Dirk R Larson; Colin L Colby; Tara K Phelps; Angela Dispenzieri; Shaji K Kumar; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

9.  Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.

Authors:  Ola Landgren; Jerry A Katzmann; Ann W Hsing; Ruth M Pfeiffer; Robert A Kyle; Edward D Yeboah; Richard B Biritwum; Yao Tettey; Andrew A Adjei; Dirk R Larson; Angela Dispenzieri; L Joseph Melton; Lynn R Goldin; Mary L McMaster; Neil E Caporaso; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

  9 in total
  3 in total

Review 1.  Genome Instability in Multiple Myeloma: Facts and Factors.

Authors:  Anna Y Aksenova; Anna S Zhuk; Artem G Lada; Irina V Zotova; Elena I Stepchenkova; Ivan I Kostroma; Sergey V Gritsaev; Youri I Pavlov
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

2.  Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma.

Authors:  Alexandra J Greenberg; Margot Cousin; Shaji Kumar; Rhett P Ketterling; Ryan A Knudson; Dirk Larson; Colin Colby; Christopher Scott; Celine M Vachon; S Vincent Rajkumar
Journal:  Eur J Haematol       Date:  2013-07-22       Impact factor: 3.674

3.  Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk.

Authors:  Rosalie G Waller; Todd M Darlington; Xiaomu Wei; Michael J Madsen; Alun Thomas; Karen Curtin; Hilary Coon; Venkatesh Rajamanickam; Justin Musinsky; David Jayabalan; Djordje Atanackovic; S Vincent Rajkumar; Shaji Kumar; Susan Slager; Mridu Middha; Perrine Galia; Delphine Demangel; Mohamed Salama; Vijai Joseph; James McKay; Kenneth Offit; Robert J Klein; Steven M Lipkin; Charles Dumontet; Celine M Vachon; Nicola J Camp
Journal:  PLoS Genet       Date:  2018-02-01       Impact factor: 5.917

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.